RE-BVS – Piemonte Repository

Sfoglia per AUTORE
CHIELLINO S
Collezione AO Ordine Mauriziano

Items : 6

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2025 Feb;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Epub 2024 Nov 10.

2025
ASL Cuneo 2
AO Ordine Mauriziano

Puglisi S; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Napoli MD; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Merler S; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Sbrana A; Chiellino S; De Giorgi U; Maruzzo M; et alii...

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Di Napoli M; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Milella M; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Chiellino S; Bimbatti D; De Giorgi U; Rebuzzi SE; et alii...

Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study. in Frontiers in immunology / Front Immunol. 2024 Jul 5;15:1361010. doi: 10.3389/fimmu.2024.1361010. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Naglieri E; Malgeri A; Cavo A; Di Napoli M; Vignani F; Nolè F; Prati G; Morelli F; Atzori F; Caffo O; Prati V; Fratino L; Tudini M; Mollica V; Sorarù M; Ricotta R; Pipitone S; Zampiva I; Chiellino S; Claps M; Fornarini G; Zucali PA; Galli L; Buti S; De Giorgi U; Maruzzo M; Rebuzzi SE; Catalano M; Signori A; et alii...

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab. in JAMA network open / JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185.

2023
AO Ordine Mauriziano

Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Procopio G; Chiellino S; Milella M; Catalano F; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; et alii...

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. in Journal of translational medicine / J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Messina M; Caffo O; Di Napoli M; Atzori F; Santini D; Soto Parra HJ; Prati V; Cortellini A; Santoni M; Sorarù M; Mollica V; Panni S; Ricotta R; Pipitone S; Fratino L; Boccardo F; Milella M; Procopio G; Naglieri E; Fantinel E; Zucali PA; Galli L; Chiellino S; Basso U; De Giorgi U; Maruzzo M; Damassi A; Fornarini G; Gandini A; et alii...

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20

2021
AO Ordine Mauriziano

Bersanelli M; Casadei C; Pierantoni F; Roviello G; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Messina C; Messina M; Pignata S; Atzori F; Stellato M; Soto Parra HJ; Prati V; Santoni M; Cortellini A; Sorarù M; Mollica V; Panni S; Ricotta R; Baldessari C; Fratino L; Tomasello L; Merler S; Procopio G; Naglieri E; Masini C; et alii...